TD Cowen Sticks to Its Buy Rating for Avita Medical (RCEL)
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Josh Jennings reiterated a Buy rating on Avita Medical (RCEL) with a $12.00 price target. This follows BTIG's recent upgrade of the stock to Buy with a $7.00 target. Jennings, who covers the Healthcare sector, has a 47% success rate on recommendations.
TD Cowen analyst Josh Jennings reiterated a Buy rating on Avita Medical today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jennings covers the Healthcare sector, focusing on stocks such as Dexcom, Boston Scientific, and TransMedics Group. According to TipRanks, Jennings has an average return of 2.8% and a 47.00% success rate on recommended stocks.
In a report released today, BTIG also upgraded the stock to a Buy with a $7.00 price target.